Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7703195 | 0.89 | MEN1 (0.42) | MEN1KMT2ACYP3A4ALOX15TSHR | |
| SCHEMBL3890589 | 0.89 | MEN1 (0.42) | MEN1KMT2ACYP3A4ALOX15TSHR | |
| SCHEMBL28476303 | 0.85 | ALOX15 (0.42) | MEN1KMT2ACYP3A4ALOX15TSHR | |
| SCHEMBL10081315 | 0.82 | TSHR (0.48) | ALOX15TSHRLMNAALDH1A1HIF1A | |
| SCHEMBL15149582 | 0.80 | TSHR (0.52) | CYP3A4TSHRLMNAALDH1A1HIF1A | |
| SCHEMBL17822154 | 0.79 | ALDH1A1 (0.33) | MEN1KMT2ACYP3A4ALOX15ALDH1A1 | |
| Pentanal SCHEMBL20856850 | 0.76 | TSHR (0.45) | MEN1KMT2ACYP3A4ALOX15TSHR | |
| SCHEMBL9391580 | 0.76 | TSHR (0.48) | TSHRALDH1A1HIF1AFAAHTRPV1 | |
| SCHEMBL12204769 | 0.76 | TSHR (0.48) | TSHRALDH1A1HIF1AFAAHTRPV1 | |
| SCHEMBL17500181 | 0.76 | TSHR (0.48) | TSHRALDH1A1HIF1AFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230245-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FLAGRANCE INGREDIENTS | GIVAUDAN SA (CH) | 2020-06-10 | — | — | EP | disclosed |
| US-10450532-B2 | Organic compounds and their use as fragrance ingredients | GIVAUDAN S.A. (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20170327769-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FRAGRANCE INGREDIENTS | GIVAUDAN S.A. (CH) | 2017-11-16 | — | — | US | disclosed |
| EP-3230245-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FLAGRANCE INGREDIENTS | Givaudan SA (CH) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091895-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FLAGRANCE INGREDIENTS | GIVAUDAN SA (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450532-B2 | Organic compounds and their use as fragrance ingredients | C9, C5, HRH1 | MEN1 1500/4885KMT2A 2128/4885CYP3A4 567/4885 |
| US-20170327769-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS AND THEIR USE AS FRAGRANCE INGREDIENTS | C5, C9, DHCR24 | MEN1 965/4885KMT2A 2438/4885CYP3A4 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.